• 1. Fe/Fe3C@C nanoparticles encapsulated in N-doped graphene–CNTs framework as an efficient bifunctional oxygen electrocatalyst for robust rechargeable Zn–air batteries?
  Zhiyan Chen,Nan Wu,Yaobing Wang,Bing Wang,Yingde Wang J. Mater. Chem. A, 2018,6, 516-526
• 2. Exchanged ligands on the surface of a giant cluster: [(MoO3)176(H2O)63(CH3OH)17Hn](32 – n)–
  Chem. Commun., 1998, 1501-1502
• 3. Establishing plasmon contribution to chemical reactions: alkoxyamines as a thermal probe?
  Olga Guselnikova,Gérard Audran,Jean-Patrick Joly,Andrii Trelin,Evgeny V. Tretyakov,Vaclav Svorcik,Oleksiy Lyutakov,Sylvain R. A. Marque Chem. Sci., 2021,12, 4154-4161
• 4. Fc microparticles can modulate the physical extent and magnitude of complement activity?
  David White,Sean R. Stowell Biomater. Sci., 2017,5, 463-474
• 5. Enabling shape memory and healable effects in a conjugated polymer by incorporating siloxane via dynamic imine bond?
  Yaling Zhang,Chunhui Dai,Shiwei Zhou,Bin Liu Chem. Commun., 2018,54, 10092-10095

Introduction to Sulfapyridine-d (CAS No: 1189863-86-2)

Sulfapyridine-d, identified by the Chemical Abstracts Service Number (CAS No) 1189863-86-2, is a derivative of sulfonamide antibiotics that has garnered significant attention in the field of pharmaceutical chemistry and medicinal research. This compound, specifically the deuterated analog of sulfapyridine, represents a sophisticated approach to drug development aimed at enhancing pharmacological properties while minimizing potential side effects. The introduction of deuterium atoms into the molecular structure of sulfapyridine-d not only modifies its metabolic stability but also influences its binding affinity to biological targets, making it a subject of extensive study in contemporary drug design.

The chemical structure of Sulfapyridine-d incorporates a sulfonamide group attached to a pyridine ring, with the presence of deuterium atoms strategically placed to optimize its pharmacokinetic profile. This modification has been shown to prolong the half-life of the compound in vivo, allowing for less frequent dosing and improved patient compliance. Furthermore, the deuterated version often exhibits reduced susceptibility to metabolic degradation pathways, which can lead to increased efficacy and lower toxicity compared to its non-deuterated counterpart.

In recent years, the development of deuterated pharmaceuticals has become a cornerstone in innovative drug design. The concept leverages the natural abundance of deuterium in water and biological systems to selectively alter metabolic pathways that degrade therapeutic agents. By incorporating deuterium atoms into key positions within a molecule, researchers can effectively "lock" certain bonds, making them less prone to enzymatic breakdown. This approach has been successfully applied to various drug classes, including antivirals, anticancer agents, and antibiotics.

Sulfapyridine-d (CAS No: 1189863-86-2) exemplifies this trend in deuterated drug development. Its application in clinical research has demonstrated promising results in treating infections caused by Gram-negative bacteria. The enhanced stability provided by the deuterium atoms allows the compound to maintain its antibacterial activity for longer periods, thereby reducing the need for additional doses and minimizing resistance development. This is particularly crucial in scenarios where timely and sustained treatment is essential for recovery.

The synthesis of Sulfapyridine-d involves advanced organic chemistry techniques that require precise control over reaction conditions and stereochemistry. The introduction of deuterium atoms can be achieved through various methods, including deuteration reactions using deuterated reagents or catalytic hydrogenation processes. These synthetic routes must be meticulously optimized to ensure high yield and purity, as any impurities could compromise the pharmacological properties of the final product.

The pharmacological profile of Sulfapyridine-d has been extensively studied in preclinical models and early-phase clinical trials. These investigations have highlighted its potential as an alternative or adjunct therapy for bacterial infections that are increasingly resistant to conventional antibiotics. The compound's ability to inhibit bacterial growth by disrupting essential metabolic pathways makes it a valuable asset in combating multidrug-resistant strains. Additionally, its improved pharmacokinetic properties suggest that it may offer better patient outcomes compared to existing treatments.

One of the most compelling aspects of Sulfapyridine-d (CAS No: 1189863-86-2) is its mechanism of action. Sulfonamides, including sulfapyridine derivatives, exert their antibacterial effects by inhibiting dihydropteroate synthase (DHPS), an enzyme critical for folic acid synthesis in bacteria. By binding competitively to DHPS, these compounds disrupt the production of tetrahydrofolate, which is essential for bacterial proliferation. The introduction of deuterium atoms into the molecule does not alter this core mechanism but enhances its duration of action by slowing down metabolic clearance.

The development of novel antibiotics is imperative due to the growing threat of antibiotic resistance worldwide. Traditional antibiotics have faced challenges with widespread resistance, necessitating innovative strategies to overcome this issue. Deuterated analogs like Sulfapyridine-d represent a forward-thinking approach that combines established pharmacological principles with cutting-edge chemical modifications. This synergy has led to compounds that are not only more effective but also more sustainable in terms of long-term therapeutic use.

In conclusion, Sulfapyridine-d, identified by CAS No: 1189863-86-2, stands as a testament to the ingenuity and progress in modern pharmaceutical research. Its unique structure and enhanced pharmacokinetic properties position it as a promising candidate for treating bacterial infections while mitigating resistance concerns. As further research unfolds, it is anticipated that additional insights into its mechanisms and applications will emerge, solidifying its role as a cornerstone in next-generation antibiotic development.

• 144-83-2(Sulfapyridine)
• 83608-12-2(Dichloroplatinum(2+); [4-(pyridin-2-ylsulfamoyl)phenyl]azanide)
• 24342-38-9(Silver,(4-amino-N-2-pyridinylbenzenesulfonamidato-NN,O)- (9CI))
• 127-57-1(Benzenesulfonamide,4-amino-N-2-pyridinyl-, sodium salt (1:1))
• 52776-76-8(4-Methyl-N-pyridin-2-yl-benzenesulfonamide)
• 89257-24-9(1-Naphthalenesulfonamide, N-2-pyridinyl-)
• 57198-81-9(Benzenediazonium, 4-[(2-pyridinylamino)sulfonyl]-, chloride)
• 83608-13-3(Platinum,bis(4-amino-N-2-pyridinylbenzenesulfonamide-N4)diiodo-, (SP-4-2)- (9CI))
• 1212-07-3(Benzenesulfonamide,N-2-pyridinyl-)
• 1363166-48-6(4-Methyl-N-(4-methyl-2-pyridyl)benzenesulfonamide Hydrochloride)